Advertisement

Topics

Th1/17 hybrid T cells offer potent and durable anti-tumor response in preclinical model

19:00 EST 8 Nov 2017 | AAAS

(Medical University of South Carolina) Adoptive cell therapy for cancer involves harvesting T cells from a patient and expanding and sometimes modifying them in the laboratory before reinfusion. It has been challenging to create T cells that are both potent and durable. In a Cell Metabolism article, Medical University of South Carolina investigators report the potent anti-tumor properties of hybrid Th1/Th17 cells that combine the cancer-fighting properties of Th1 cells and the ability of Th17 cells to self-renew and regenerate.

Original Article: Th1/17 hybrid T cells offer potent and durable anti-tumor response in preclinical model

NEXT ARTICLE

More From BioPortfolio on "Th1/17 hybrid T cells offer potent and durable anti-tumor response in preclinical model"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...